The effect of furosemide in the prevention of contrast-induced nephropathy in STEMI patients undergoing Percutaneous Coronary Intervention (PCI)

Phase 3

Recruiting

• Conditions: Condition 1: Myocardial infarction. Condition 2: Contrast-induced nephropathy.; Acute myocardial infarction,unspecified; I21.9

• Registration Number: IRCT20230312057694N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 234

Inclusion Criteria

Those who are willing to participate in the study
Patients whose clinical information is complete
Patients whose disease has been confirmed as STEMI and are candidates for angiography and angioplasty

Exclusion Criteria

Patients who do not agree to participate in the study
Patients whose clinical information is not complete
Patients with heart failure
Dialysis patients who do not pass urine

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Renal function and occurrence of renal disorders after the use of contrast. Timepoint: After a period of 24 and 72 hours after the injection of furosemide and serum. Method of measurement: Test: Blood Urea Nitrogen(Bun),Creatinine(Cr), Glomerular Filtration Rate (GFR).